Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: nolimitz who wrote (189088)	3/11/2009 11:27:42 AM
From: ACAN	Respond to of 208838

GNBT; volume is on track to equal yesterday or even exceed it. I guess a lot of that news is what folks were waiting for. Nowi if the FDA allows sale in the US, it could get back into its old groove. Generex Biotechnology Provides Update On Generex Oral-lyn(tm) in India Wednesday March 11, 9:30 am ET Indian Licensee Secures Over 100 Orders in First Month of Marketing WORCESTER, Mass., March 11, 2009 (GLOBE NEWSWIRE) -- On the heels of yesterday's announcement of positive study data from its Phase III protocol for its flagship product Generex Oral-lyn(tm), Generex Biotechnology Corporation (NasdaqCM:GNBT - News) (http://www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today provided an update on Generex Oral-lyn(tm) sales in India, where the product is marketed and sold by Shreya Life Sciences Pvt. Ltd. (http://www.shreya.co.in). ADVERTISEMENT Generex Oral-lyn(tm) was approved in India for importation, commercial marketing and sale for the treatment of Type 1 and Type 2 diabetes and has been marketed under the brand name Oral Recosulin(tm) since January 27, 2009 in Mumbai and in the cities of Bangalore, Delhi, Kolkata, Chennai and Cochin since February 3, 2009. Sales managers at Shreya Life Sciences, along with key Shreya marketing and medical personnel, have been actively involved in promoting the product to key opinion leaders and physicians in the region. Following the initial marketing campaign, Shreya Life Sciences has to date procured Oral Recosulin(tm) orders from more than 60 doctors for over 100 patients. ``We believe that the rapid progress that our licensee has made in India reflects the demand for a pain-free insulin product,'' said Anna Gluskin, Generex's President and Chief Executive Officer. ``Since the educational introduction of Generex Oral-lyn(tm) in India last November, Shreya has designed and implemented a strategy to identify target markets in India and establish an initial customer base from which we expect sales to continue to grow.'' Generex Oral-lyn(tm) is designed to offer a simple, convenient, fast, effective, flexible, familiar and pain-free alternative to prandial injections of insulin. Generex Oral-lyn(tm) is a proprietary oral insulin spray product, the first non-injectable buccal insulin approved in India. Unlike inhaled insulin products, buccally absorbed Generex Oral-lyn(tm) does not have pulmonary side effects, and is safely and efficiently delivered without pain via Generex's proprietary RapidMist(tm) device, which looks like a simple asthma inhaler, but provides complete absorption through the buccal mucosa (lining of the mouth) with no deposit in the lungs.